PortfoliosLab logoPortfoliosLab logo
ISIN
US3722791098
CUSIP
372279109
IPO Date
Mar 27, 2019

Highlights

Market Cap
$241.46M
Enterprise Value
$289.32M
EPS (TTM)
-$0.33
Total Revenue (TTM)
$116.80M
Gross Profit (TTM)
$122.47M
EBITDA (TTM)
-$1.40M
Year Range
$3.41 - $4.93
ROA (TTM)
-7.61%
ROE (TTM)
-31.42%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Genfit

Often compared with GNFT:
GNFT vs. MRK

Performance

GNFT Performance Chart

Genfit (GNFT) is up 0.0% since the beginning of the year. At $5 per share, GNFT is trading just below its 52-week high of $5. Investors who bought $1,000 worth of GNFT shares 5 years ago would now be looking at an investment worth $1,158.


Loading charts...

S&P 500 Index

Returns By Period

Genfit (GNFT) has returned 0.00% so far this year and 13.36% over the past 12 months.


Genfit

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
13.36%
3Y*
5.16%
5Y*
2.97%
10Y*

Benchmark (S&P 500 Index)

1D
0.13%
1M
5.25%
YTD
11.16%
6M
11.43%
1Y
28.20%
3Y*
21.12%
5Y*
12.66%
10Y*
13.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GNFT Monthly Returns History

Based on dividend-adjusted daily data since Mar 27, 2019, GNFT's average daily return is +0.02%, while the average monthly return is +0.15%. At this rate, an investment would double in approximately 38.5 years.

Historically, 39% of months were positive and 61% were negative. The best month was Dec 2021 with a return of +56.3%, while the worst month was May 2020 at -75.4%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.

On a daily basis, GNFT closed higher 44% of trading days. The best single day was Dec 17, 2021 with a return of +53.3%, while the worst single day was May 12, 2020 at -67.7%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20260.00%0.00%0.00%0.00%0.00%0.00%
20250.40%-6.97%-1.44%19.74%10.13%-17.41%5.64%1.65%-5.00%1.58%25.65%30.55%
20242.60%-12.15%2.59%-1.69%48.00%-30.31%16.62%3.09%37.56%-2.01%-28.03%-11.76%-3.51%
2023-2.26%2.56%-6.82%-2.44%1.75%-13.02%-0.00%1.13%-8.66%-0.00%-2.14%20.31%-12.28%
2022-18.10%-8.42%6.67%-10.00%-0.28%-10.31%33.57%-0.02%-15.12%10.41%-6.70%16.73%-12.22%
20214.17%0.00%-7.60%-6.93%-6.98%-5.00%-1.58%10.70%-10.63%-6.76%-7.25%56.25%4.17%

Benchmark Metrics

Genfit has an annualized alpha of -3.03%, beta of 0.42, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since March 28, 2019.

  • This stock participated in 99.45% of S&P 500 Index downside but only -9.50% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.42 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-3.03%
Beta
0.42
0.02
Upside Capture
-9.50%
Downside Capture
99.45%

Return for Risk

Risk / Return Rank

GNFT ranks 55 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


GNFT Risk / Return Rank: 5555
Overall Rank
GNFT Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
GNFT Sortino Ratio Rank: 5151
Sortino Ratio Rank
GNFT Omega Ratio Rank: 5454
Omega Ratio Rank
GNFT Calmar Ratio Rank: 5858
Calmar Ratio Rank
GNFT Martin Ratio Rank: 5858
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Genfit (GNFT) and compare them to S&P 500 Index.


GNFTBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.38

2.39

-2.01

Sortino ratio

Return per unit of downside risk

0.88

3.25

-2.38

Omega ratio

Gain probability vs. loss probability

1.14

1.43

-0.30

Calmar ratio

Return relative to maximum drawdown

0.81

3.11

-2.30

Martin ratio

Return relative to average drawdown

1.92

14.38

-12.47

Dividends

Dividend History


Genfit doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Genfit. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Genfit was 89.42%, occurring on Apr 9, 2025. The portfolio has not yet recovered.

The current Genfit drawdown is 81.09%.


Related event

Drawdown

Fall

Recovery

Underwater

2025 selloff2025
-89.42%Apr 2025
6y 2d
7y 1moApr 2019 - now
2019 pullback2019
-2.03%Apr 2019
2d4d
6dApr 2019 - Apr 2019

Drawdown Indicators


GNFTBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-89.42%

-56.78%

-32.64%

Max Drawdown (1Y)

Largest decline over 1 year

-21.64%

-9.10%

-12.54%

Max Drawdown (3Y)

Largest decline over 3 years

-57.11%

-18.90%

-38.21%

Max Drawdown (5Y)

Largest decline over 5 years

-57.11%

-25.43%

-31.68%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-81.09%

0.00%

-81.09%

Average Drawdown

Average peak-to-trough decline

-74.62%

-10.72%

-63.90%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.94%

1.97%

+7.97%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Genfit over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Genfit is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GNFT relative to other companies in the Biotechnology industry. Currently, GNFT has a P/S ratio of 2.1. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for GNFT in comparison with other companies in the Biotechnology industry. Currently, GNFT has a P/B value of 4.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with GNFT

Add Genfit to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with GNFT